BIIB 📈 Biogen - Overview

Biogen Inc. is a biotechnology company that focuses on the discovery, development, manufacturing, and delivery of therapies for neurological and neurodegenerative diseases. The company operates globally, with a presence in the United States, Europe, Germany, Asia, and other international markets. Its product portfolio includes a range of treatments for multiple sclerosis, such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which cater to the diverse needs of patients with this condition. Additionally, Biogen offers SPINRAZA for spinal muscular atrophy, ADUHELM for Alzheimer's disease, and FUMADERM for plaque psoriasis, demonstrating its commitment to addressing various neurological and neurodegenerative disorders.

Biogen has also established itself as a significant player in the biosimilars market, with products like BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. These biosimilars offer more affordable alternatives to reference biologics, increasing access to essential treatments for patients. The company's portfolio is further diversified by its offerings for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions, including RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab. This broad range of products underscores Biogen's dedication to advancing patient care across multiple therapeutic areas.

Biogen's research and development pipeline is robust, with various products in different stages of development for the treatment of multiple sclerosis, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars. The company collaborates with other industry leaders, such as Acorda Therapeutics, Alkermes Pharma Ireland, Denali Therapeutics, Eisai, Genentech, Neurimmune, Ionis Pharmaceuticals, Samsung Bioepis, Sangamo Therapeutics, and Sage Therapeutics, to drive innovation and accelerate the development of new therapies. A notable collaboration is with Fujirebio, aimed at identifying and developing blood-based biomarkers for tau pathology in the brain, which could significantly advance the understanding and treatment of neurodegenerative diseases. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. is listed on the NASDAQ under the ticker symbol BIIB, with its common stock classified under the GICS Sub Industry: Biotechnology.